Myrtelle Inc.
Last verified 2026-06-05. JSON
The funding figures on this page are attributed, not sourced: a publisher is on record but no document URL is. How we mark provenance.
| Total raised | $55.2Mattributed |
|---|---|
| Latest round | Funding round, $55.2M, 2025-12-23attributed |
| Founded | unknown |
| Headquarters | New York, New York |
| Industry | biotechnology |
| Stage | unknown |
| Website | myrtellegtx.com |
Myrtelle develops gene therapies for myelin-based neurological disorders such as leukodystrophies that have few existing treatments. It serves patients with rare genetic white matter diseases of the central nervous system, with Canavan disease as its lead program.
Funding rounds
| Date | Round | Amount | Lead |
|---|---|---|---|
| 2025-12-23 | Funding round | $55.2M | undisclosed |
Detected tech stack
addtoany, addtoany share buttons 1.1, contact form 7 6.1.5, facebook pixel, jquery 3.7.1, jquery migrate 3.4.1, mysql, nginx, php, pixelyoursite, python, slick
Provenance
| Fact | Status | Basis |
|---|---|---|
| Funding round, $55.2M | attributed | sec-edgar named as publisher. No document URL on file. |
| Total raised $55.2M | attributed | sec-edgar named as publisher. No document URL on file. |
| Company existence | self-reported | myrtellegtx.com, read 2026-06-05 |
| Description | self-reported | myrtellegtx.com, read 2026-06-05 |
Nothing on this page is sourced yet. A sourced fact links to a document that states it.
Change history
| Date | Fact | Change | Basis |
|---|---|---|---|
| 2026-09-25Latest round: seed, $55.2M, 2025-12-23 → Funding round, $55.2M, 2025-12-23, sec-edgar, No document URL on file | Latest round | seed, $55.2M, 2025-12-23 → Funding round, $55.2M, 2025-12-23 | sec-edgar, No document URL on file |
Records begin 2026-09-24. All changes